Gökhan MORAY, Ebru Hatice AYVAZOGLU SOY, Hüseyin Onur AYDIN

Can platelet Iymphocyte ratio and neutrophil to lymphocyte ratio be used as prognostic predictors for hepatocellular carcinoma?

Aim: To investigate the predictive value of platelet to lymphocyte and neutrophil to lymphocyte ratios for hepatocellular carcinomaoutcomesMaterial and Methods: 37 hepatocellular carcinoma patients were retrospectively collected. All of the hepatocellular carcinomapatients were treated with conventional methods; transarterial chemoembolization, radiofrequency ablation or both. The patientand tumor characteristics, platelet to lymphocyte ratio and neutrophil to lymphocyte ratio were recorded. The association betweenplatelet to lymphocyte ratio and neutrophil to lymphocyte ratio and tumor free survival rates, recurence rates, need of repeatedconventional therapy were analyzed.Results: The mean MELD (model for end stage liver disease) score of 37 hepatocellular carcinoma patients was 10.75±4.484(mean age 59.59±17.23 years). High platelet to lymphocyte ratio and neutrophil to lymphocyte ratio were found to be associatedwith hepatocellular carcinoma recurrence (p0.05). Platelet to lymphocyte ratio and neutrophil to lymphocyte ratios were significantlyhigh in patients who had repated transarterial chemoembolisation, radiofrequency ablation or both (p

PDF

___

1. Bosch FX, Ribes J, Cleries R, et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005;9:191-211.
2. Thomas MB, Jaffe D, Choti MM, et al. Hepatocellular carcinoma; consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010;28:3994-4005.
3. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
4. European association for the study of the liver; european organisation for research and treatment of cancer. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
5. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.
6. Prasad KR, Young RS, Burra P, et al. Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver Transpl 2011;17:S81-9.
7. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-403.
8. Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008;85:1726-32.
9. Li WX, Li Z, Gao PJ, et al. Histological differentiation predicts post-liver transplantation survival time. Clin Res Hepatol Gastroenterol 2014;38:201-8.
10. Chen Y, Chen K, Xiao X, et al. Pretreatment neutrophil-tolymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. BMC Cancer 2016;16:320-5.
11. Wu SJ, Lin YX, Ye H, et al. Lymphocyte to monocyte ratio and prognostic nutritional index predict survival outcomes of hepatitis B virusassociated hepatocellular carcinoma patients after curativehepatectomy. J Surg Oncol 2016;114:202-10.
12. Toso C, Asthana S, Bigam DL. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009;49:832-8.
13. You J, Zhu GQ, Xie L, et al. Preoperative platelet to lymphocyte ratio is a valuable prognostic biomarker in patients with colorectal cancer. Oncotarget 2016;7:25516-27.
14. Lai Q, Castro Santa E, Rico Juri JM, et al. Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transpl Int 2014;27:32-41.